A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies
Identifieur interne : 002156 ( Pmc/Corpus ); précédent : 002155; suivant : 002157A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies
Auteurs : Alexandre Chan ; Michael C. Cameron ; Benjamin Garden ; Christine B. Boers-Doets ; Katja Schindler ; Joel B. Epstein ; Jennifer Choi ; Laura Beamer ; Eric Roeland ; Elvio G. Russi ; René-Jean Bensadoun ; Yi Ling Teo ; Raymond J. Chan ; Vivianne Shih ; Jane Bryce ; Judith Raber-Durlacher ; Peter Arne Gerber ; César O. Freytes ; Bernardo Rapoport ; Nicole Leboeuf ; Vincent Sibaud ; Mario E. LacoutureSource :
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [ 0941-4355 ] ; 2015.
Abstract
Dermatologic adverse events (dAE) in cancer treatment are frequent with use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.
A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments.
Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index [DLQI], and DIELH-24), and two were symptom-specific (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitors-18 [FACT-EGFRI-18] and Hand-Foot Syndrome 14 [HFS-14]).
While there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.
Url:
DOI: 10.1007/s00520-014-2564-x
PubMed: 25564221
PubMed Central: 4996115
Links to Exploration step
PMC:4996115Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies</title>
<author><name sortKey="Chan, Alexandre" sort="Chan, Alexandre" uniqKey="Chan A" first="Alexandre" last="Chan">Alexandre Chan</name>
<affiliation><nlm:aff id="A1">Department of Pharmacy, Faculty of Science, National University of Singapore, Rep. of Singapore</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cameron, Michael C" sort="Cameron, Michael C" uniqKey="Cameron M" first="Michael C." last="Cameron">Michael C. Cameron</name>
<affiliation><nlm:aff id="A2">University of South Florida Morsani College of Medicine, Tampa, FL, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Garden, Benjamin" sort="Garden, Benjamin" uniqKey="Garden B" first="Benjamin" last="Garden">Benjamin Garden</name>
<affiliation><nlm:aff id="A3">Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Boers Doets, Christine B" sort="Boers Doets, Christine B" uniqKey="Boers Doets C" first="Christine B." last="Boers-Doets">Christine B. Boers-Doets</name>
<affiliation><nlm:aff id="A4">IMPAQTT, Wormer, The Netherlands, and Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schindler, Katja" sort="Schindler, Katja" uniqKey="Schindler K" first="Katja" last="Schindler">Katja Schindler</name>
<affiliation><nlm:aff id="A3">Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="A5">Department of Dermatology, Medical University of Vienna, Vienna, Austria</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Epstein, Joel B" sort="Epstein, Joel B" uniqKey="Epstein J" first="Joel B." last="Epstein">Joel B. Epstein</name>
<affiliation><nlm:aff id="A6">Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Choi, Jennifer" sort="Choi, Jennifer" uniqKey="Choi J" first="Jennifer" last="Choi">Jennifer Choi</name>
<affiliation><nlm:aff id="A7">Yale University School of Medicine, New Haven, CT, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Beamer, Laura" sort="Beamer, Laura" uniqKey="Beamer L" first="Laura" last="Beamer">Laura Beamer</name>
<affiliation><nlm:aff id="A8">School of Nursing & Health Studies, Northern Illinois University, DeKalb, IL, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Roeland, Eric" sort="Roeland, Eric" uniqKey="Roeland E" first="Eric" last="Roeland">Eric Roeland</name>
<affiliation><nlm:aff id="A9">Moores Cancer Center, University of California San Diego, La Jolla, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Russi, Elvio G" sort="Russi, Elvio G" uniqKey="Russi E" first="Elvio G." last="Russi">Elvio G. Russi</name>
<affiliation><nlm:aff id="A10">Department of Radiation Oncology, AO. S. Croce e Carle Teaching Hospital, Cuneo, Italy</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bensadoun, Rene Jean" sort="Bensadoun, Rene Jean" uniqKey="Bensadoun R" first="René-Jean" last="Bensadoun">René-Jean Bensadoun</name>
<affiliation><nlm:aff id="A11">Centre de Haute Energie, Nice, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Teo, Yi Ling" sort="Teo, Yi Ling" uniqKey="Teo Y" first="Yi Ling" last="Teo">Yi Ling Teo</name>
<affiliation><nlm:aff id="A1">Department of Pharmacy, Faculty of Science, National University of Singapore, Rep. of Singapore</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chan, Raymond J" sort="Chan, Raymond J" uniqKey="Chan R" first="Raymond J." last="Chan">Raymond J. Chan</name>
<affiliation><nlm:aff id="A12">Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Shih, Vivianne" sort="Shih, Vivianne" uniqKey="Shih V" first="Vivianne" last="Shih">Vivianne Shih</name>
<affiliation><nlm:aff id="A13">National Cancer Centre Singapore, Singapore, Rep. of Singapore</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bryce, Jane" sort="Bryce, Jane" uniqKey="Bryce J" first="Jane" last="Bryce">Jane Bryce</name>
<affiliation><nlm:aff id="A14">National Cancer Institute, Naples, Italy</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Raber Durlacher, Judith" sort="Raber Durlacher, Judith" uniqKey="Raber Durlacher J" first="Judith" last="Raber-Durlacher">Judith Raber-Durlacher</name>
<affiliation><nlm:aff id="A15">Department of Oral and Maxillofacial Surgery, Academic Medical Center Amsterdam and Department of Medical Dental Interaction Academic Centre of Dentistry Amsterdam, The Netherlands</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gerber, Peter Arne" sort="Gerber, Peter Arne" uniqKey="Gerber P" first="Peter Arne" last="Gerber">Peter Arne Gerber</name>
<affiliation><nlm:aff id="A16">Heinrich Heine University, Düsseldorf, Germany</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Freytes, Cesar O" sort="Freytes, Cesar O" uniqKey="Freytes C" first="César O." last="Freytes">César O. Freytes</name>
<affiliation><nlm:aff id="A17">University of Texas Health Science Center at San Antonio, San Antonio, TX, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rapoport, Bernardo" sort="Rapoport, Bernardo" uniqKey="Rapoport B" first="Bernardo" last="Rapoport">Bernardo Rapoport</name>
<affiliation><nlm:aff id="A18">The Medical Oncology Centre of Rosebank, Johannesburg, South Africa</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Leboeuf, Nicole" sort="Leboeuf, Nicole" uniqKey="Leboeuf N" first="Nicole" last="Leboeuf">Nicole Leboeuf</name>
<affiliation><nlm:aff id="A19">Dana-Farber Cancer Institute, Boston, MA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sibaud, Vincent" sort="Sibaud, Vincent" uniqKey="Sibaud V" first="Vincent" last="Sibaud">Vincent Sibaud</name>
<affiliation><nlm:aff id="A20">Cancer University Institute Of Toulouse Oncopole, Toulouse, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lacouture, Mario E" sort="Lacouture, Mario E" uniqKey="Lacouture M" first="Mario E." last="Lacouture">Mario E. Lacouture</name>
<affiliation><nlm:aff id="A3">Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25564221</idno>
<idno type="pmc">4996115</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996115</idno>
<idno type="RBID">PMC:4996115</idno>
<idno type="doi">10.1007/s00520-014-2564-x</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">002156</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002156</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies</title>
<author><name sortKey="Chan, Alexandre" sort="Chan, Alexandre" uniqKey="Chan A" first="Alexandre" last="Chan">Alexandre Chan</name>
<affiliation><nlm:aff id="A1">Department of Pharmacy, Faculty of Science, National University of Singapore, Rep. of Singapore</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Cameron, Michael C" sort="Cameron, Michael C" uniqKey="Cameron M" first="Michael C." last="Cameron">Michael C. Cameron</name>
<affiliation><nlm:aff id="A2">University of South Florida Morsani College of Medicine, Tampa, FL, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Garden, Benjamin" sort="Garden, Benjamin" uniqKey="Garden B" first="Benjamin" last="Garden">Benjamin Garden</name>
<affiliation><nlm:aff id="A3">Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Boers Doets, Christine B" sort="Boers Doets, Christine B" uniqKey="Boers Doets C" first="Christine B." last="Boers-Doets">Christine B. Boers-Doets</name>
<affiliation><nlm:aff id="A4">IMPAQTT, Wormer, The Netherlands, and Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Schindler, Katja" sort="Schindler, Katja" uniqKey="Schindler K" first="Katja" last="Schindler">Katja Schindler</name>
<affiliation><nlm:aff id="A3">Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</nlm:aff>
</affiliation>
<affiliation><nlm:aff id="A5">Department of Dermatology, Medical University of Vienna, Vienna, Austria</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Epstein, Joel B" sort="Epstein, Joel B" uniqKey="Epstein J" first="Joel B." last="Epstein">Joel B. Epstein</name>
<affiliation><nlm:aff id="A6">Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Choi, Jennifer" sort="Choi, Jennifer" uniqKey="Choi J" first="Jennifer" last="Choi">Jennifer Choi</name>
<affiliation><nlm:aff id="A7">Yale University School of Medicine, New Haven, CT, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Beamer, Laura" sort="Beamer, Laura" uniqKey="Beamer L" first="Laura" last="Beamer">Laura Beamer</name>
<affiliation><nlm:aff id="A8">School of Nursing & Health Studies, Northern Illinois University, DeKalb, IL, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Roeland, Eric" sort="Roeland, Eric" uniqKey="Roeland E" first="Eric" last="Roeland">Eric Roeland</name>
<affiliation><nlm:aff id="A9">Moores Cancer Center, University of California San Diego, La Jolla, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Russi, Elvio G" sort="Russi, Elvio G" uniqKey="Russi E" first="Elvio G." last="Russi">Elvio G. Russi</name>
<affiliation><nlm:aff id="A10">Department of Radiation Oncology, AO. S. Croce e Carle Teaching Hospital, Cuneo, Italy</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bensadoun, Rene Jean" sort="Bensadoun, Rene Jean" uniqKey="Bensadoun R" first="René-Jean" last="Bensadoun">René-Jean Bensadoun</name>
<affiliation><nlm:aff id="A11">Centre de Haute Energie, Nice, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Teo, Yi Ling" sort="Teo, Yi Ling" uniqKey="Teo Y" first="Yi Ling" last="Teo">Yi Ling Teo</name>
<affiliation><nlm:aff id="A1">Department of Pharmacy, Faculty of Science, National University of Singapore, Rep. of Singapore</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Chan, Raymond J" sort="Chan, Raymond J" uniqKey="Chan R" first="Raymond J." last="Chan">Raymond J. Chan</name>
<affiliation><nlm:aff id="A12">Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Shih, Vivianne" sort="Shih, Vivianne" uniqKey="Shih V" first="Vivianne" last="Shih">Vivianne Shih</name>
<affiliation><nlm:aff id="A13">National Cancer Centre Singapore, Singapore, Rep. of Singapore</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bryce, Jane" sort="Bryce, Jane" uniqKey="Bryce J" first="Jane" last="Bryce">Jane Bryce</name>
<affiliation><nlm:aff id="A14">National Cancer Institute, Naples, Italy</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Raber Durlacher, Judith" sort="Raber Durlacher, Judith" uniqKey="Raber Durlacher J" first="Judith" last="Raber-Durlacher">Judith Raber-Durlacher</name>
<affiliation><nlm:aff id="A15">Department of Oral and Maxillofacial Surgery, Academic Medical Center Amsterdam and Department of Medical Dental Interaction Academic Centre of Dentistry Amsterdam, The Netherlands</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Gerber, Peter Arne" sort="Gerber, Peter Arne" uniqKey="Gerber P" first="Peter Arne" last="Gerber">Peter Arne Gerber</name>
<affiliation><nlm:aff id="A16">Heinrich Heine University, Düsseldorf, Germany</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Freytes, Cesar O" sort="Freytes, Cesar O" uniqKey="Freytes C" first="César O." last="Freytes">César O. Freytes</name>
<affiliation><nlm:aff id="A17">University of Texas Health Science Center at San Antonio, San Antonio, TX, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rapoport, Bernardo" sort="Rapoport, Bernardo" uniqKey="Rapoport B" first="Bernardo" last="Rapoport">Bernardo Rapoport</name>
<affiliation><nlm:aff id="A18">The Medical Oncology Centre of Rosebank, Johannesburg, South Africa</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Leboeuf, Nicole" sort="Leboeuf, Nicole" uniqKey="Leboeuf N" first="Nicole" last="Leboeuf">Nicole Leboeuf</name>
<affiliation><nlm:aff id="A19">Dana-Farber Cancer Institute, Boston, MA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Sibaud, Vincent" sort="Sibaud, Vincent" uniqKey="Sibaud V" first="Vincent" last="Sibaud">Vincent Sibaud</name>
<affiliation><nlm:aff id="A20">Cancer University Institute Of Toulouse Oncopole, Toulouse, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lacouture, Mario E" sort="Lacouture, Mario E" uniqKey="Lacouture M" first="Mario E." last="Lacouture">Mario E. Lacouture</name>
<affiliation><nlm:aff id="A3">Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</title>
<idno type="ISSN">0941-4355</idno>
<idno type="eISSN">1433-7339</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Purpose</title>
<p id="P1">Dermatologic adverse events (dAE) in cancer treatment are frequent with use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.</p>
</sec>
<sec id="S2"><title>Methods</title>
<p id="P2">A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index [DLQI], and DIELH-24), and two were symptom-specific (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitors-18 [FACT-EGFRI-18] and Hand-Foot Syndrome 14 [HFS-14]).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">While there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.</p>
</sec>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9302957</journal-id>
<journal-id journal-id-type="pubmed-jr-id">8479</journal-id>
<journal-id journal-id-type="nlm-ta">Support Care Cancer</journal-id>
<journal-id journal-id-type="iso-abbrev">Support Care Cancer</journal-id>
<journal-title-group><journal-title>Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer</journal-title>
</journal-title-group>
<issn pub-type="ppub">0941-4355</issn>
<issn pub-type="epub">1433-7339</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">25564221</article-id>
<article-id pub-id-type="pmc">4996115</article-id>
<article-id pub-id-type="doi">10.1007/s00520-014-2564-x</article-id>
<article-id pub-id-type="manuscript">NIHMS806627</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Chan</surname>
<given-names>Alexandre</given-names>
</name>
<degrees>PharmD, MPH</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Cameron</surname>
<given-names>Michael C.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Garden</surname>
<given-names>Benjamin</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Boers-Doets</surname>
<given-names>Christine B.</given-names>
</name>
<degrees>RN</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Schindler</surname>
<given-names>Katja</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Epstein</surname>
<given-names>Joel B.</given-names>
</name>
<degrees>DMD, MSD</degrees>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Choi</surname>
<given-names>Jennifer</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Beamer</surname>
<given-names>Laura</given-names>
</name>
<degrees>PhD, DNP</degrees>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Roeland</surname>
<given-names>Eric</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Russi</surname>
<given-names>Elvio G.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bensadoun</surname>
<given-names>René-Jean</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A11">11</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Teo</surname>
<given-names>Yi Ling</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Chan</surname>
<given-names>Raymond J.</given-names>
</name>
<degrees>PhD, RN</degrees>
<xref ref-type="aff" rid="A12">12</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Shih</surname>
<given-names>Vivianne</given-names>
</name>
<degrees>PharmD</degrees>
<xref ref-type="aff" rid="A13">13</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Bryce</surname>
<given-names>Jane</given-names>
</name>
<degrees>MSN</degrees>
<xref ref-type="aff" rid="A14">14</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Raber-Durlacher</surname>
<given-names>Judith</given-names>
</name>
<degrees>DDS, PhD</degrees>
<xref ref-type="aff" rid="A15">15</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Gerber</surname>
<given-names>Peter Arne</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A16">16</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Freytes</surname>
<given-names>César O.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A17">17</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Rapoport</surname>
<given-names>Bernardo</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A18">18</xref>
</contrib>
<contrib contrib-type="author"><name><surname>LeBoeuf</surname>
<given-names>Nicole</given-names>
</name>
<xref ref-type="aff" rid="A19">19</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sibaud</surname>
<given-names>Vincent</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A20">20</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lacouture</surname>
<given-names>Mario E.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
Department of Pharmacy, Faculty of Science, National University of Singapore, Rep. of Singapore</aff>
<aff id="A2"><label>2</label>
University of South Florida Morsani College of Medicine, Tampa, FL, USA</aff>
<aff id="A3"><label>3</label>
Department of Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA</aff>
<aff id="A4"><label>4</label>
IMPAQTT, Wormer, The Netherlands, and Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands</aff>
<aff id="A5"><label>5</label>
Department of Dermatology, Medical University of Vienna, Vienna, Austria</aff>
<aff id="A6"><label>6</label>
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA</aff>
<aff id="A7"><label>7</label>
Yale University School of Medicine, New Haven, CT, USA</aff>
<aff id="A8"><label>8</label>
School of Nursing & Health Studies, Northern Illinois University, DeKalb, IL, USA</aff>
<aff id="A9"><label>9</label>
Moores Cancer Center, University of California San Diego, La Jolla, CA, USA</aff>
<aff id="A10"><label>10</label>
Department of Radiation Oncology, AO. S. Croce e Carle Teaching Hospital, Cuneo, Italy</aff>
<aff id="A11"><label>11</label>
Centre de Haute Energie, Nice, France</aff>
<aff id="A12"><label>12</label>
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia</aff>
<aff id="A13"><label>13</label>
National Cancer Centre Singapore, Singapore, Rep. of Singapore</aff>
<aff id="A14"><label>14</label>
National Cancer Institute, Naples, Italy</aff>
<aff id="A15"><label>15</label>
Department of Oral and Maxillofacial Surgery, Academic Medical Center Amsterdam and Department of Medical Dental Interaction Academic Centre of Dentistry Amsterdam, The Netherlands</aff>
<aff id="A16"><label>16</label>
Heinrich Heine University, Düsseldorf, Germany</aff>
<aff id="A17"><label>17</label>
University of Texas Health Science Center at San Antonio, San Antonio, TX, USA</aff>
<aff id="A18"><label>18</label>
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa</aff>
<aff id="A19"><label>19</label>
Dana-Farber Cancer Institute, Boston, MA, USA</aff>
<aff id="A20"><label>20</label>
Cancer University Institute Of Toulouse Oncopole, Toulouse, France</aff>
<author-notes><corresp id="FN1">Address for all communications: Mario E Lacouture, MD., Memorial Sloan-Kettering Cancer Center, Rockefeller Outpatient Pavilion, Suite 228, 160 E 53<sup>rd</sup>
St., NY, NY 10022 USA, Ph: 212-610-0079, Fax: 212-308-0739, <email>lacoutum@mskcc.org</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>13</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub"><day>07</day>
<month>1</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub"><month>8</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>24</day>
<month>8</month>
<year>2016</year>
</pub-date>
<volume>23</volume>
<issue>8</issue>
<fpage>2231</fpage>
<lpage>2244</lpage>
<pmc-comment>elocation-id from pubmed: 10.1007/s00520-014-2564-x</pmc-comment>
<abstract><sec id="S1"><title>Purpose</title>
<p id="P1">Dermatologic adverse events (dAE) in cancer treatment are frequent with use of targeted therapies. These dAEs have been shown to have significant impact on health-related quality of life (HRQoL). While standardized assessment tools have been developed for physicians to assess severity of dAEs, there is a discord between objective and subjective measures. The identification of patient-reported outcome (PRO) instruments useful in the context of targeted cancer therapies is therefore important in both the clinical and research settings for the overall evaluation of dAEs and their impact on HRQoL.</p>
</sec>
<sec id="S2"><title>Methods</title>
<p id="P2">A comprehensive, systematic literature search of published articles was conducted by two independent reviewers in order to identify PRO instruments previously utilized in patient populations with dAEs from targeted cancer therapies. The identified PRO instruments were studied to determine which HRQoL issues relevant to dAEs were addressed, as well as the process of development and validation of these instruments.</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P3">Thirteen articles identifying six PRO instruments met the inclusion criteria. Four instruments were general dermatology (Skindex-16©, Skindex-29©, Dermatology Life Quality Index [DLQI], and DIELH-24), and two were symptom-specific (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitors-18 [FACT-EGFRI-18] and Hand-Foot Syndrome 14 [HFS-14]).</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P4">While there are several PRO instruments that have been tested in the context of targeted cancer therapy, additional work is needed to develop new instruments and to further validate the instruments identified in this study in patients receiving targeted therapies.</p>
</sec>
</abstract>
<kwd-group><kwd>Targeted cancer therapy</kwd>
<kwd>dermatologic adverse events</kwd>
<kwd>patient-reported outcomes</kwd>
<kwd>health-related quality of life</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002156 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002156 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Pmc |étape= Corpus |type= RBID |clé= PMC:4996115 |texte= A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:25564221" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |